New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | all day >>
06:33 EDTBKBNY Mellon upgraded to Neutral from Sell at Goldman
Goldman upgraded BNY Mellon to Neutral based on balanced risk/reward and progress on costs. Price target is $34.
06:33 EDTHASHasbro reports Q3 Franchise brands up 36%
Subscribe for More Information
06:32 EDTAFFXAffymetrix licenses Peptide Groove technology
Subscribe for More Information
06:32 EDTASTAsterias announces NGA with CIRM for AST-OPC1 Phase 1/2a clinical trial
Asterias Biotherapeutics announced that the company has signed a Notice of Grant Award, or NGA, with the California Institute of Regenerative Medicine, or CIRM, effective October 1. The NGA provides for the immediate release of Clinical Development payments and the release of additional grant funds pursuant to the previously announced $14.3M CIRM grant award for clinical development of Asterias' product, AST-OPC1. The grant provides non-dilutive funding to initiate a Phase 1/2a clinical trial of AST-OPC1 in patients with complete cervical spinal cord injury and other product development activities for AST-OPC1. The new Phase 1/2a clinical trial is designed to assess safety and activity of escalating doses of AST-OPC1 for complete cervical spinal cord injuries, the first targeted indication for AST-OPC1. The trial will be an open-label, single-arm study testing three escalating doses of AST-OPC1 in 13 patients with subacute, C5-C7, neurologically-complete cervical spinal cord injury. These individuals have essentially lost all sensation and movement below their injury site with severe paralysis of the upper and lower limbs. AST-OPC1 will be administered 14 to 30 days post-injury. Patients will be followed by neurological exams to assess the safety and activity of the product. Selection of the clinical trial sites is well underway, and the Company expects to begin patient enrollment during 1Q15.
06:31 EDTHASHasbro reports Q3 adjusted EPS $1.46, consensus $1.45
Subscribe for More Information
06:28 EDTAGN, ACT, TEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
06:26 EDTCHA, CHU, CHLEU, China settle telecoms case at Joint Committee
Intensive discussions between the European Commission and the Chinese government were concluded by an amicable settlement on the trade defense investigation into Chinese telecoms. The Commission took the official decision that it no longer considers it necessary to pursue this investigation. Regarding telecoms, the main points of the settlement include tasking an independent body with the monitoring of the Chinese and EU telecoms networks markets, guaranteeing access to the relevant Chinese standard setting body for European companies without discrimination, equal treatment of companies bidding for publically funded research and development projects and the EU and China will also advance the work of the International Working Group on Export Credits, whose objective is to adopt sectorial and horizontal disciplines in the field. The talks culminated on October 18 at the EU-China Joint Committee. Some telecom companies in China include China Telecom (CHA), China Unicom (CHU) and China Mobile (CHL). Reference Link
06:26 EDTYHOOYahoo to unveil turnaround, M&A strategy, WSJ reports
Subscribe for More Information
06:23 EDTCNNXCONE Midstream initiated with a Neutral at Citigroup
Subscribe for More Information
06:22 EDTAMBIAmbit Biosciences downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Ambit Biosciences to Neutral citing the pending acquisition by Daiichi Sankyo.
06:22 EDTGOOGYouTube's Robert Kyncl considering leaving company, NY Post reports
Subscribe for More Information
06:21 EDTAGNCAmerican Capital downgraded to Market Perform from Outperform at JMP Securities
Subscribe for More Information
06:20 EDTFCXFreeport McMoRan upgraded to Neutral from Sell at Citigroup
Citigroup upgraded Freeport McMoRan to Neutral citing the recent pullback in shares. Citi keeps a $31 price target for the stock.
06:19 EDTCNXCONSOL upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
06:18 EDTWRWestar Energy downgraded to Neutral from Buy at UBS
Subscribe for More Information
06:18 EDTTSCDYTesco executives in South Korea face prosecution, Telegraph reports
Tesco executives could face prosecution in South Korea over claims that the retailer's Homeplus arm sold personal data of over 5M customers to insurance companies, the Telegraph reports. In addition to Homeplus being probed, CEO Sung-Hwan Do and other executives could be investigated for their role in the scandal. Reference Link
06:18 EDTAHGPAlliance Holdings upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
06:17 EDTNEMNewmont Mining upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
06:15 EDTSHLDSears files automatic mixed securities shelf
06:15 EDTLNVGYLenovo cuts prices for 7- and 8-inch tablets, DigiTimes Research reports
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use